Vantage’s roundup of medtech news you might have missed includes Boston Scientific hitting its 11th biz dev deal of the year.
Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.
Sequencing data is all well and good, but what does it mean?
Can the company's $1.5bn valuation be justified when last year it took just $23.5m in orders?
Many small groups are up thanks to takeover speculation, and this may end up being self-defeating.